TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,694 | -35.1% | 4,440 | +11.5% | 0.00% | -33.3% |
| Q2 2023 | $61,179 | -22.1% | 3,983 | +14.1% | 0.00% | -25.0% |
| Q1 2023 | $78,535 | -1.9% | 3,492 | -8.3% | 0.00% | 0.0% |
| Q4 2022 | $80,061 | -9.1% | 3,807 | +6.5% | 0.00% | 0.0% |
| Q3 2022 | $88,088 | -9.1% | 3,575 | -10.6% | 0.00% | 0.0% |
| Q2 2022 | $96,872 | -6.0% | 3,998 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $103,028 | -79.9% | 3,998 | -75.7% | 0.00% | -42.9% |
| Q4 2021 | $511,322 | +28.0% | 16,473 | 0.0% | 0.01% | +16.7% |
| Q3 2021 | $399,470 | +66.2% | 16,473 | 0.0% | 0.01% | +100.0% |
| Q2 2021 | $240,341 | -38.5% | 16,473 | +5.3% | 0.00% | -50.0% |
| Q1 2021 | $390,706 | – | 15,647 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |